Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiFAST phase II study of fixed-dose faster ramp-up epcoritamab plus lenalidomide in third-line relapsed or refractory large B-cell lymphoma after second-line CAR T-cell therapy
2025-520895-24-00Phase 2Authorised
- Sponsor
- LYSARC
- Start
- Sep 2026
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Primary endpoint: Overall response rate. Planned start Sep 2026; status: authorised.
02
Drugs
epcoritamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2025-520895-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520895-24-00.